EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
18 nov. 2024 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...
EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments
07 nov. 2024 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
– Announced positive interim data for DURAVYU 2.7mg in DME demonstrating meaningful, early and sustained visual acuity gains, strong anatomical control and a continued favorable safety profile; BCVA...
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
04 nov. 2024 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives...
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
31 oct. 2024 16h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives...
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering
29 oct. 2024 21h47 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives...
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
28 oct. 2024 17h14 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives...
EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema
28 oct. 2024 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
- DURAVYU 2.7mg demonstrated an early and sustained improvement in BCVA with a gain of +8.9 letters compared to baseline - – DURAVYU 2.7mg demonstrated an early and sustained anatomical improvement...
EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration
24 oct. 2024 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
– Second Phase 3 LUCIA pivotal trial first patient dosing expected by end of 2024 – – Topline data anticipated in 2026 – WATERTOWN, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- EyePoint...
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16 oct. 2024 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16 sept. 2024 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...